MedPath

Community-based Microalbuminuria Screening in Patients With Hypertension

Conditions
Hypertension
Microalbuminuria
Registration Number
NCT03596840
Lead Sponsor
Shanghai Zhongshan Hospital
Brief Summary

This study evaluates the effectiveness of different anti-hypertensive drugs on patients with hypertension and microalbuminuria.

Detailed Description

This is a a real world registry study. All patients with hypertension in community hospitals in China will be eligible . Patient demographics, medical history, clinical characteristics, physical examination, laboratory tests (including UCAR, blood routine, urine routine, blood biochemistry, and ECG), antihypertensive drugs (including: ACEI/ ARB, thiazide diuretics, CCB, beta-blockers, alpha-blockers, and other antihypertensive drugs used in real-life clinical practice in other communities.) will be recorded. All patients are anticipated to be followed up for 12-month. Effectiveness of different antihypertensive medications on Urine Albumin-to-Creatinine Ratio (UACR) will be evaluted.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
3000
Inclusion Criteria
  • Patients with essential hypertension;
  • Urinary albumin/creatinine ratio in random urine samples is 30-300 mg/g
  • Age >=18
  • Understand and sign informed consent
Read More
Exclusion Criteria
  • This is a real-world registry study and does not set exclusion criteria
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Urine Albumin-to-Creatinine Ratio (UCAR)12 months

Differences in UCAR between with ACEI/ARB and without ACEI/ARB

Secondary Outcome Measures
NameTimeMethod
Combined endpoints: re-admission, cardiovascular events, and all-cause mortality12 months

Differences in Combined endpoints between with ACEI/ARB and without ACEI/ARB

© Copyright 2025. All Rights Reserved by MedPath